Literature DB >> 18683100

Overcoming the extracellular matrix barrier to improve intratumoral spread and therapeutic potential of oncolytic virotherapy.

Chae-Ok Yun1.   

Abstract

Genetically attenuated viruses are under development as selectively replicating antitumoral agents. However, the inability of adenoviral vectors to disseminate throughout a solid tumor mass remains a major obstacle in realizing the full potential of this therapeutic modality. Therefore, strategies aimed at increasing the anatomical distribution of a replicating virus within tumor tissues are highly desirable. Tumor extracellular matrix (ECM) is characterized by distorted blood vessels and activated connective tissue cells that produce a collagen-rich matrix. Elevation of interstitial fluid pressure acts as a physical barrier to the transport of macromolecules across the ECM. This review discusses advances in the development of oncolytic viruses that modulate the ECM to enhance viral spread within tumor tissues, several of which may also be applicable to non-replicating viral systems. In addition, the effect of apoptosis on viral spread throughout the tumor mass and 3-dimensional model systems for the study of viral spread are presented.

Entities:  

Mesh:

Year:  2008        PMID: 18683100

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN: 1464-8431


  22 in total

1.  Negative regulation-resistant p53 variant enhances oncolytic adenoviral gene therapy.

Authors:  Taeyoung Koo; Il-Kyu Choi; Minjung Kim; Jung-Sun Lee; Eonju Oh; Jungho Kim; Chae-Ok Yun
Journal:  Hum Gene Ther       Date:  2012-02-21       Impact factor: 5.695

2.  HSV Recombinant Vectors for Gene Therapy.

Authors:  Roberto Manservigi; Rafaela Argnani; Peggy Marconi
Journal:  Open Virol J       Date:  2010-06-18

Review 3.  Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?

Authors:  Ryuichi Kanai; Hiroaki Wakimoto; Tooba Cheema; Samuel D Rabkin
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

4.  Perfusion Pressure Is a Critical Determinant of the Intratumoral Extravasation of Oncolytic Viruses.

Authors:  Amber Miller; Rebecca Nace; Camilo Ayala-Breton C; Michael Steele; Kent Bailey; Kah Whye Peng; Stephen J Russell
Journal:  Mol Ther       Date:  2015-12-09       Impact factor: 11.454

5.  Hepatoma targeting peptide conjugated bio-reducible polymer complexed with oncolytic adenovirus for cancer gene therapy.

Authors:  Joung-Woo Choi; Hyun Ah Kim; Kihoon Nam; Youjin Na; Chae-Ok Yun; SungWan Kim
Journal:  J Control Release       Date:  2015-10-03       Impact factor: 9.776

6.  Oncolytic adenovirus expressing soluble TGFβ receptor II-Fc-mediated inhibition of established bone metastases: a safe and effective systemic therapeutic approach for breast cancer.

Authors:  Zebin Hu; Helen Gerseny; Zhenwei Zhang; Yun-Ju Chen; Arthur Berg; Zhiling Zhang; Stuart Stock; Prem Seth
Journal:  Mol Ther       Date:  2011-06-28       Impact factor: 11.454

Review 7.  Glioma virus therapies between bench and bedside.

Authors:  Johanna K Kaufmann; E Antonio Chiocca
Journal:  Neuro Oncol       Date:  2014-01-26       Impact factor: 12.300

8.  Antiglioma oncolytic virotherapy: unattainable goal or a success story in the making?

Authors:  Mahua Dey; Brenda Auffinger; Maciej S Lesniak; Atique U Ahmed
Journal:  Future Virol       Date:  2013-07       Impact factor: 1.831

9.  The HSV-2 mutant DeltaPK induces melanoma oncolysis through nonredundant death programs and associated with autophagy and pyroptosis proteins.

Authors:  A G Colunga; J M Laing; L Aurelian
Journal:  Gene Ther       Date:  2009-10-01       Impact factor: 5.250

10.  Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma.

Authors:  Jennifer Altomonte; Sabrina Marozin; Roland M Schmid; Oliver Ebert
Journal:  Mol Ther       Date:  2009-10-06       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.